The trial is testing RGN-259 (Thymosin beta 4), a sterile, preservative-free eye drop developed for patients with dry eye syndrome, neurotrophic keratopathy (NK), and other corneal disorders. The
The application now will be reviewed by the European Commission, which has the authority to approve medicines for the European Union (EU). Bristol-Myers Squibb senior vice president, head
Under an agreement signed with Novartis in October 2014, Oxford BioMedica will undertake process development and manufacturing for the lentiviral vector associated with the new programme. Oxford BioMedica
These studies are designed to assess the change in menstrual blood loss utilizing the alkaline hematin method, comparing baseline to month six of treatment. Additional secondary efficacy endpoints
The event organised to mark the granting of this loan will take place at Transgene’s headquarters in Illkirch-Graffenstaden, in the presence of Ambroise Fayolle, EIB Vice-President responsible for
The FDA criteria for BTD require preliminary clinical evidence that demonstrates a drug may have substantial improvement on at least one clinically significant endpoint over available therapy. The
The company looks forward to sharing these data with health authorities soon. Bristol-Myers Squibb senior vice president, head of oncology development Michael Giordano said: "With the results of
Epic Sciences president and CEO Murali Prahalad said: "We have entered into an era where biomarkers are beginning to direct therapeutic decisions. What remains difficult is clinical validation
The NDA will be considered officially filed 60 days from the date of the completion of the submission, or February 20, 2016. The FDA granted Priority Review to
Preclinical studies of RAD1901 have shown consistent and robust single agent anti-tumor activity in multiple wild type and ESR1-mutant breast cancer models and tumor regression when combined with
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.